TB Alternative Assets Ltd. Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

TB Alternative Assets Ltd. bought a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the first quarter, Holdings Channel.com reports. The fund bought 70,800 shares of the company’s stock, valued at approximately $706,000.

A number of other large investors have also recently modified their holdings of RXRX. Swiss National Bank boosted its stake in shares of Recursion Pharmaceuticals by 1.6% during the 3rd quarter. Swiss National Bank now owns 284,100 shares of the company’s stock valued at $2,173,000 after purchasing an additional 4,600 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter valued at about $117,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Recursion Pharmaceuticals by 15.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,157,966 shares of the company’s stock valued at $8,858,000 after purchasing an additional 157,189 shares in the last quarter. UBS Group AG boosted its stake in shares of Recursion Pharmaceuticals by 103.1% during the 3rd quarter. UBS Group AG now owns 342,679 shares of the company’s stock valued at $2,621,000 after purchasing an additional 173,954 shares in the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Recursion Pharmaceuticals by 15.4% during the 3rd quarter. Deutsche Bank AG now owns 59,688 shares of the company’s stock valued at $457,000 after purchasing an additional 7,973 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded down $0.62 during trading hours on Wednesday, reaching $8.76. 5,247,778 shares of the company’s stock traded hands, compared to its average volume of 5,943,834. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $16.75. The firm has a market cap of $2.08 billion, a PE ratio of -5.51 and a beta of 0.86. The firm has a 50-day simple moving average of $8.81 and a 200 day simple moving average of $9.94.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The company had revenue of $13.80 million during the quarter, compared to analysts’ expectations of $11.10 million. During the same period last year, the company posted ($0.34) EPS. Recursion Pharmaceuticals’s revenue was up 14.0% on a year-over-year basis. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday. KeyCorp lifted their price target on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 23,124 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $7.58, for a total value of $175,279.92. Following the completion of the transaction, the chief financial officer now directly owns 1,231,055 shares of the company’s stock, valued at $9,331,396.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Recursion Pharmaceuticals news, CFO Michael Secora sold 23,124 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $7.58, for a total value of $175,279.92. Following the completion of the transaction, the chief financial officer now directly owns 1,231,055 shares of the company’s stock, valued at $9,331,396.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Gibson sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $10.10, for a total transaction of $404,000.00. Following the transaction, the chief executive officer now directly owns 1,043,524 shares of the company’s stock, valued at $10,539,592.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 281,359 shares of company stock valued at $2,410,876. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.